Abion Inc. Stock

A203400

KR7203400007

Biotechnology & Medical Research

End-of-day quote Korea S.E. 14/08/2026			5-day change	1st Jan Change
676.00 ^KRW	-2.03%		+4.48%	-78.40%

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
04/04/25	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE

ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.

Employees

Sector

Biotechnology & Medical Research

Calendar

10-08 Significant Split/Dividend

More about the company

Quotes

Date	Price	Change	Volume
14/08/26	₩676.00	-2.03%	2,169,199
13/08/26	₩690.00	-7.88%	3,252,426
12/08/26	₩749.00	-23.57%	4,228,686
11/08/26	₩980.00	+16.53%	8,846,447

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Stock Market
Stocks
A203400 Stock

As early as today, start finding the best investment opportunities!

Market Cap	60.91B 43.08M 37.19M 34.89M 31.78M 59.76M 4.12B 60.59M 409M 160M 2.06B 162M 158M 6.86B	P/E 2024	-4.02x	P/E 2025	-7.21x
Enterprise Value	32.57B 23.04M 19.89M 18.66M 17M 31.96M 2.2B 32.4M 219M 85.72M 1.1B 86.5M 84.63M 3.67B	EV / Sales 2024	282x	EV / Sales 2025	288x
Free-Float	67.24%	Yield 2024 *	-	Yield 2025	-

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
04/04/25	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE
30/12/24	Nuon Co., Ltd. completed the acquisition of 4.06% stake in ABION Inc. from KPM TECH Co., Ltd..	CI
26/12/24	KPM TECH Co., Ltd. announced that it has received KRW 5.999999711 billion in funding from ABION Inc.	CI
23/12/24	Nuon Co., Ltd. agreed to acquire 4.06% stake in ABION Inc. from KPM TECH Co., Ltd. for KRW 8 billion.	CI
23/12/24	ABION Inc. announced that it has received KRW 8.0011152 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
18/12/24	KPM TECH Co., Ltd. announced that it expects to receive KRW 5.999999711 billion in funding from ABION Inc.	CI
05/12/24	ABION Inc. completed the acquisition of 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc..	CI
05/12/24	ABION Inc. announced that it has received KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
11/11/24	ABION Inc. announced that it expects to receive KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
11/11/24	ABION Inc. agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. for KRW 20.1 billion.	CI
28/10/24	ABION Inc. announced that it expects to receive KRW 9.999995616 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
28/12/23	Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	CI

1 day	-2.03%
1 week	+4.48%
Current month	+1.96%
1 month	+0.15%
3 months	-66.70%
6 months	-81.01%
Current year	-78.40%

1 week	650	1,093
1 month	587	1,093
Current year	570	4,335
1 year	570	4,510
3 years	570	7,277.78
5 years	570	14,694.44
10 years	570	14,694.44

Manager	Title	Age	Since
Young-Gi Shin CEO	Chief Executive Officer	55	01/08/2010
Seong-Yun Woo DFI	Director of Finance/CFO	45	28/03/2025
Gi-Ryong Jang COO	Chief Operating Officer	46	01/01/2026

Abion Inc. Stock

Stocks

A203400

KR7203400007

Biotechnology & Medical Research

Valuation: Abion Inc.

Chart: Abion Inc.

Latest news : Abion Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Abion Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Director	Title	Age	Since
Young-Gi Shin BRD	Director/Board Member	55	31/12/2014
Jin-Wook Yang BRD	Director/Board Member	56	25/03/2022
Geun-Chul Park BRD	Director/Board Member	70	-

Date	Insider	Type	Quantity	% Market Cap.
8/12/25	Sun-mi Chang	Free	27	0.0001%
8/12/25	Yang-mi Lim	Buy	115	0.0002%
8/12/25	Yang-mi Lim	Free	92	0.0002%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABION INC.	-2.03%	+4.48%	-80.99%	-85.34%	43.09M
WUXI APPTEC CO., LTD.	+4.80%	+7.80%	+70.64%	+114.21%	70.07B
ARGENX SE	+17.12%	+11.50%	+54.42%	+87.30%	52.87B
INSMED INCORPORATED	+3.70%	-4.77%	+0.41%	+484.07%	27.02B
WUXI BIOLOGICS (CAYMAN) INC.	+2.26%	+0.65%	+49.19%	+10.30%	23.61B
BIONTECH SE	-1.60%	-1.29%	-19.31%	-19.10%	23.38B
PHARMAESSENTIA CORPORATION	-6.00%	+13.71%	+244.39%	+443.26%	19.43B
GENMAB A/S	+3.80%	+5.25%	+40.50%	-16.41%	18.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.38%	-3.15%	+20.39%	+589.77%	15.85B
EXELIXIS, INC.	+2.11%	-1.21%	+36.57%	+149.14%	12.7B
Average	+2.45%	-1.83%	+41.62%	+175.72%	26.37B
Weighted average by Cap.	+5.10%	+2.24%	+56.27%	+170.78%

	2024	2025
Net sales	760M 537K 464K 435K 396K 745K 51.38M 756K 5.1M 2M 25.74M 2.02M 1.97M 85.62M	880M 623K 537K 504K 459K 863K 59.52M 875K 5.91M 2.32M 29.82M 2.34M 2.29M 99.2M
Net income	-43.38B -30.68M -26.49M -24.85M -22.64M -42.56M -2.93B -43.15M -291M -114M -1.47B -115M -113M -4.89B	-29.06B -20.56M -17.75M -16.65M -15.16M -28.51M -1.97B -28.91M -195M -76.48M -985M -77.18M -75.51M -3.28B
Net Debt	14.05B 9.94M 8.58M 8.05M 7.33M 13.78M 950M 13.97M 94.33M 36.96M 476M 37.3M 36.49M 1.58B	-28.33B -20.04M -17.3M -16.23M -14.78M -27.8M -1.92B -28.18M -190M -74.56M -960M -75.24M -73.61M -3.19B